Mark McDaniel, MD
Family Medicine · Saraland, ALNPI 1518997014
Payments from drug & device makers
Across 444 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$990
- AbbVie$752
- AstraZeneca$564
- Johnson & Johnson$347
- Bayer$325
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,697100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 108 | $1,220 |
| Lilly USA, LLC | 59 | $990 |
| AbbVie(2 entities) | 54 | $752 |
| AstraZeneca | 35 | $564 |
| Johnson & Johnson | 23 | $347 |
| Bayer | 18 | $325 |
| Shield Therapeutics Inc | 15 | $294 |
| Amarin Pharma, Inc. | 15 | $286 |
| Idorsia Pharmaceuticals US Inc | 11 | $173 |
| GSK | 10 | $172 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $154 |
| Pfizer | 10 | $142 |
| Exact Sciences | 7 | $142 |
| Daiichi Sankyo Inc. | 7 | $130 |
| Astellas Pharma US Inc | 6 | $94 |
| Abbott | 4 | $80 |
| Amgen | 5 | $78 |
| Boehringer Ingelheim | 5 | $74 |
| Mylan Specialty L.p. | 4 | $68 |
| Lundbeck LLC | 4 | $66 |
| Dexcom, Inc. | 4 | $65 |
| Kowa Pharmaceuticals America, Inc. | 5 | $63 |
| Phathom Pharmaceuticals, Inc. | 4 | $61 |
| Genentech USA, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Eisai Inc. | 2 | $25 |
| Novartis | 2 | $24 |
| Insulet Corporation | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Biowound Solutions, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
How this compares
$6,716 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 513 | $614,096 |
| OzempicSemaglutide | 272 | $305,275 |
| EliquisApixaban | 128 | $114,632 |
| FarxigaDapagliflozin Propanediol | 118 | $108,941 |
| JardianceEmpagliflozin | 99 | $90,752 |
| TrulicityDulaglutide | 41 | $47,259 |
| XareltoRivaroxaban | 48 | $37,804 |
| RybelsusSemaglutide | 20 | $35,168 |
| LinzessLinaclotide | 48 | $32,579 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $27,834 |
| JanuviaSitagliptin Phosphate | 29 | $25,042 |
| EntrestoSacubitril/Valsartan | 30 | $22,687 |
| ViberziEluxadoline | 12 | $15,979 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $14,507 |
| MyrbetriqMirabegron | 23 | $13,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $990 | $661,355554 claims |
| Novo NordiskOzempic, Rybelsus | $1,220 | $340,443292 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $564 | $125,271147 claims |
| PfizerEliquis | $142 | $114,632128 claims |
| Boehringer IngelheimJardiance | $74 | $90,75299 claims |
| AbbVieLinzess, Viberzi | $752 | $48,55860 claims |
| Johnson & JohnsonXarelto, Invokana | $347 | $43,69059 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $172 | $28,64160 claims |
| MerckJanuvia | $15 | $25,04229 claims |
| NovartisEntresto | $24 | $22,68730 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $13,02323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Saraland
- Howard RubensteinSaraland$3.3M
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.